Target intelligence / Profile preview

NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (NDUFB9)

Target
NDUFB9
Molecular classification
Enzyme (accessory subunit of mitochondrial Complex I, NADH:ubiquinone oxidoreductase)[1][3][10], LYRM protein superfamily (contains LYR motif)[1][2]
01

Overview

NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (NDUFB9) is an accessory subunit of mitochondrial complex I (NADH:ubiquinone oxidoreductase), the largest enzyme complex of the electron transport chain, embedded in the inner mitochondrial membrane. NDUFB9 is not directly involved in electron transfer catalysis but is necessary for structural integrity and function of complex I, facilitating the transfer of electrons from NADH to ubiquinone, which is key for ATP synthesis via oxidative phosphorylation. Mutations or reductions in NDUFB9 are linked to mitochondrial complex I deficiency, associated with a spectrum of disorders including neurological, muscular, and metabolic diseases as well as certain cancers. The gene product is a 22kDa protein of the LYRM family, characterized by a conserved LYR motif[1][2][3][4][10][12].

Other names
LYRM3UQOR22CI-B22B22Complex I B22 subunitLYR motif-containing protein 3MC1DN24NDUB9NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 9[1][3][5][10]
02

Mechanism of action

Inhibition of complex I disrupts electron flow and ATP production; drugs targeting complex I generally impair mitochondrial function[1][3]

03

Biological functions

Mitochondrial electron transport (NADH to ubiquinone)[1][7]Oxidative phosphorylation[3][4]Cellular energy production[1][3]
04

Disease associations

Mitochondrial complex I deficiency[3][12]Neurodegenerative disease (associated through complex I malfunction)[3]Cardiomyopathy[3]Liver disease[3]Cancer (down-regulation may promote breast cancer proliferation and metastasis)[12]
05

Safety considerations

Inhibiting or reducing complex I activity can lead to impaired cellular ATP production, increased ROS, and mitochondrial dysfunction, posing risks of lactic acidosis, neuromuscular or organ dysfunction[1][3]
06

Interacting drugs

None specifically reported for NDUFB9; complex I inhibitors (e.g., rotenone, piericidin A) target overall complex I, not this subunit directly[1][3]
07

Biomarkers

Reduced NDUFB9 expression or activity can serve as a biomarker for complex I deficiency and possibly for certain cancers[12]

Beyond the preview

Go deeper on NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (NDUFB9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (NDUFB9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call